Fulcrum Therapeutics, Inc. (FULC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.68-2.39%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · FULC
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||
| Revenues | — | — | 80.0 | 2.8 | 6.3 | 19.2 | 8.8 | — |
| Operating Expenses & Income | ||||||||
| R&D Expenses | 56.2 | 56.1 | 63.4 | 71.8 | 76.8 | 69.7 | 59.0 | 71.1 |
| Operating Income | (96.0) | (84.8) | (21.9) | (110.7) | (112.6) | (81.1) | (71.6) | (84.2) |
| Earnings from Continuing Operations | ||||||||
| Asset Writedown | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | ||||||||
| Net Income | (85.0) | (74.9) | (9.7) | (97.3) | (109.9) | (80.8) | (70.8) | (82.7) |
| Per Share | ||||||||
| Basic EPS | (1.11) | (1.18) | (0.16) | (1.59) | (2.44) | (2.29) | (2.79) | — |
| Diluted EPS | (1.11) | (1.18) | (0.16) | (1.59) | (2.44) | (2.29) | (2.79) | — |
| Basic Weighted Avg Shares | 76.3 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | — |
| Diluted Weighted Avg Shares | 76.3 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | — |
| Supplemental | ||||||||
| EBIT | (96.0) | (84.8) | (21.9) | (110.7) | (112.6) | (81.1) | (71.6) | (84.2) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.